Фармакологічне обґрунтування вибору оптимального складу нового вагінального гелю з ресвератролом і гіалуроновою кислотою

Abstract

The aim of the work study – screening determination of the activity of test samples of gels with resveratrol and hyaluronic acid on a model of hypoestrogenism in rats to identify a leader sample with the optimal content of resveratrol in the dosage form composition. The vaginal gels of a combined composition were developed under the supervision of a doctor of pharmaceutical sciences, professor O. A. Ruban at the Department of Plant Technology NFaU. To model the hypoestrogen state in female rats, the main hormone-producing gland, the ovaries, were removed. Vaginal gels were administered intravaginally 1 time per day for 28 days. The pharmacological effectiveness of the test samples was carried out by such indicators as change in body weight of rats (since women during menopause are prone to increase body weight) and body temperature at the root of the tail (this indicator is considered equivalent to the symptom of «hot flashes» in women), microbiological examination of the vaginal biotope, the pH value of the vaginal secretion, the macro- and microscopic state of the vaginal mucosa, which corresponds to the clinical manifestations of hypoestrogenic state.According to the results of the studied parameters evaluation, a gel with 0,5 % resveratrol showed the highest pharmacological activity: estrogen-like effect was the largest among all test samples of vaginal gels with various concentrations of resveratrol, namely 0,5 %, 1 %, 2 % and 3 %. Under the course application the vaginal gels helped to normalize body weight and body temperature at the root of the tail, a microbiological state and the pH of the vaginal secretion. When the vaginal gel was administered to female rats after bilateral ovariectomy, it prevented the development of dystrophic macro- and microscopic changes in the vaginal mucosa, and as a result led to the restoration of the state of the epithelial plate of the vagina of animals, and the effectiveness of the new vaginal gel exceeded the effect of the reference drug.According to the results of screening studies, a gel with 0,5 % resveratrol was recognized as the leader sample and recommended as the final composition of the dosage form for further in-depth pharmacological studies.